METTL21EP: A Potential Drug Target and Biomarker (G121952)

Target Name: METTL21EP

NCBI ID: G121952

METTL21EP

Other Name(s): Methyltransferase like 21E, pseudogene | methyltransferase like 21E, pseudogene | METTL21CP1

METTL21EP: A Potential Drug Target and Biomarker

Introduction

Methyltransferases are a class of enzymes that are involved in the methylation of gene promoters, which plays a crucial role in gene expression and cell development. Methylation of promoters can either activate or repress gene expression, depending on the context. During development, methylation of promoters is critical for the regulation of gene expression and the formation of tissues with specific functions. However, methylation also has been implicated in the development and progression of many diseases, including cancer, neurodegenerative diseases, and psychiatric disorders.

METTL21EP, a pseudogene for the enzyme methyltransferase-like 21E (Methyltransferase-like 21E), is a promising drug target and biomarker for several reasons. In this article, we will discuss the structure and function of METTL21EP, its potential as a drug target, and its potential as a biomarker for various diseases.

Structure and Function of METTL21EP

METTL21EP is a single-domain protein that contains 21 amino acid residues. The protein has a calculated molecular mass of 31.1 kDa and a pI of 4.7. METTL21EP is a pseudogene, which means that it encodes a protein that is similar to its functional counterpart in Escherichia coli but does not have the full-length gene.

The METTL21EP protein has a single transmembrane domain that consists of a catalytic core and a cytoplasmic tail. The catalytic core contains the active site for methylation, which consists of a conserved core domain that is involved in the binding of methyl groups. of a variable region that is involved in the protein's stability and localization to the cell membrane.

METTL21EP has been shown to have methyltransferase activity, which involves the transfer of methyl groups from the substrate DNA to the protein. The methyltransferase activity of METTL21EP is dependent on its specific substrate and the methylation state of the cell. METTL21EP can methylate the promoter region of a gene, which can either activate or repress gene expression.

Potential as a Drug Target

METTL21EP has been identified as a potential drug target due to its unique structure and function. The methylation-dependent methyltransferase activity of METTL21EP makes it an attractive target for drugs that are designed to inhibit methylation. This is because METTL21EP is involved in the regulation of gene expression, which is a key step in the development and progression of many diseases.

One of the main advantages of targeting METTL21EP is its specificity. METTL21EP is designed to bind specifically to DNA-protein interactions, which makes it a good candidate for drugs that are targeted to specific methylation states. This also means that METTL21EP is less likely to have unintended effects on other genes that are not targeted by the drug.

Another advantage of targeting METTL21EP is its druggability. METTL21EP has a calculated molecular mass of 31.1 kDa, which makes it a large protein that is relatively easy to target with small molecules. Additionally, because METTL21EP is a pseudogene, it has a high degree of sequence homogeneity, which makes it easier to identify and modify the target site.

Potential as a Biomarker

METTL21EP has also been shown to be a potential biomarker for several diseases. One of the main advantages of using METTL21EP as a biomarker is its specificity. METTL21EP is designed to bind specifically to DNA-protein interactions, which makes it a good candidate for biomarkers that are targeted to specific methylation states. This also means that METTL21EP is less likely to have unintended effects on other genes that are not targeted by the biomarker.

Another advantage of using METTL21EP as a biomarker is its sensitivity to changes in methylation state. METTL21EP has been shown to be involved in the regulation of gene expression, which is a key step in the development and progression of many diseases. This means that changes in Methylation status can be used as a biomarker for the disease.

Conclusion

METTL21EP is a pseudogene that encodes an enzyme with methyltransferase activity. Its unique structure and function make it a promising drug target and biomarker for several diseases. The specificity of METTL21EP, as well as its potential to target methylation states, makes it an attractive target for drugs that are designed to inhibit methylation. Additionally, METTL21EP's sensitivity to changes in methylation status makes it a promising biomarker for diseases that are characterized by changes in methylation status. Further studies are needed to fully understand the potential of METTL21EP as a drug target and biomarker .

Protein Name: Methyltransferase Like 21E, Pseudogene

Functions: Protein-lysine methyltransferase

The "METTL21EP Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about METTL21EP comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets